instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: Attorney and Democratic state Sen. Jacob Candelaria recently filed a lawsuit in state district court on behalf of Joe Montano, who said authorities recently seized his medical cannabis, KOAT-TV reports. According to court documents, correctional officers searched Montano's home while he was on house arrest, found the marijuana, and put him in jail for a month as punishment. The petition is seeking a judge to order the jail to allow him to possess and use his medical marijuana. State lawmakers passed a measure last year to allow people on house arrest to use medical marijuana. In a statement, Metropolitan Detention Center Chief of Corrections Ralph Fernadez said Community Custody Program inmates are considered in jail custody, and medical marijuana use is prohibited in the detention center. Claim: New Mexico man in house arrest sues to use medical marijuana.
answer:
A New Mexico man serving a house arrest sentence for drunken driving is suing to be allowed to use medical marijuana.

question:
Paragraph: "Johnny carries a lot of clout in our league when you hear the other coaches," Brey said as he prepares for his 20th season at Notre Dame. "We take him for granted - he just rolls out of bed and goes 15 (points) and 12 (rebounds) like it's nothing." The 6-foot-9 senior Mooney averaged team highs of 14.1 points and 11.2 rebounds last season for the Fighting Irish, who lost 63 games to injuries and illnesses during a 14-19 campaign that included just three wins and a last-place finish in the Atlantic Coast Conference. "They had their back sides handed to them . we're older, we're healthier, we're better," Brey said. The return to health of guards Robby Carmody, Rex Pflueger, Nikola Djogo and forward Juwan Durham, the maturation of sophomores Prentiss Hubb, Dane Goodwin, Nate Laszewski and Chris Doherty, and senior T.J. Gibbs making amends for his junior slump have created excitement for the season opener Nov. 6 at North Carolina. "The guys are playing at a higher level, sharing the basketball and feeding off each other," Mooney said. "Coming off last year, no one's giving us a shot. So we have to play with a chip on our shoulder to get the job done and prove these people wrong." Hubb, who started 29 games at point guard, thinks Mooney's leadership is just fine, even if his coach would like more confidence from his standout. "He's a role model for everyone on this team," said Hubb, who averaged 8.1 points and nearly four assists last season. RALLYING AROUND REX Things went south quickly for the Irish after Pflueger, averaging 8.1 points and 4.7 rebounds at the time, tore left knee ligaments last December. The injury came at the same time his mother was diagnosed with brain cancer. She died early in September and the team attended her memorial service in California. "Some of the stuff they've gone through with Rex and his mother's situation that's kind of done some things to our team's dynamic," Brey said. "It speaks highly of our coaching staff and players," said Pflueger, now a grad student working on his MBA who is not being rushed to be ready for the opener. "It's an act of kindness you don't see often." MEDIC In addition to Pflueger missing the final 23 games following knee surgery, Carmody missed his final 24 and Djogo his final six with torn labrums that were surgically repaired. The 6-foot-11 Durham, who missed six games with leg issues, averaged 2.3 blocks when healthy in 27 games. THE HUBB Brey likes what he sees in the 6-foot-3 Hubb at the point. "He moves more confidently and is more vocal," Brey said. "He and T.J. (Gibbs) have been pretty good." BEAT THE CLOCK Instead of the usual 30-second shot clock, Brey used a 20-second version during the preseason. "That way we have to play quick and you can't think too much. You've got to make a decision," he said. SCHEDULE Besides North Carolina, the Irish host Boston College on Dec. 7 in the pre-holiday portion of the 20-game ACC schedule. Notre Dame also has non-conference games with Maryland, UCLA and Indiana before starting the final 18 games of league play at Syracuse Jan. 4. Brey said he and Orange coach Jim Boeheim talked about the league's big three North Carolina, Duke and defending champion Virginia on the summer scouting trail. "He said, 'You know, we're all playing for fourth,'" chuckled Brey, whose team is picked seventh. "He never minces words, obviously." __ More AP college basketball: https://apnews.com/Collegebasketball and https://twitter.com/AP_Top25 Claim: Mooney and healthy teammates have Brey, Irish encouraged.
answer:
As long as John Mooney keeps putting up double-doubles and his teammates stay healthy, coach Mike Brey feels pretty good about Notre Dame's chances this season.

question:
Paragraph: The vaccine, developed by U.S. drugmaker Merck & Co, is already being used under emergency guidelines to try to protect people against the spread of a deadly Ebola outbreak in Democratic Republic of Congo. It protects against the Zaire strain of the Ebola virus - the one that most commonly causes outbreaks. The shot is also being reviewed under a fast-track system by regulators in the United States, with a decision expected in the first quarter of next year. "This vaccine has already saved many lives in the current Ebola outbreak, and the decision by European regulators will help it to eventually save many more," the WHO's director-general Tedros Adhanom Ghebreyesus said in a statement. The Congo Ebola outbreak has killed more than 2,100 people since the middle of last year. It is the second-largest Ebola outbreak in history, after a 2013-16 epidemic in West Africa that killed more than 11,300. The Merck vaccine, which the company has now brand-named Ervebo, is likely to get a full marketing license from the European Commission in a few weeks. Roger Perlmutter, president of Merck Research Laboratories, said the company's priority now was to get regulatory approval of its Ervebo manufacturing site in Germany so that licensed supply of the vaccine "can be used to support global public health preparedness". Merck's vaccine is being used in Congo in a so-called "ring vaccination" approach, in which people who may have been in contact with someone newly infected with Ebola are traced and offered the shot to protect them. Charlie Weller, head of vaccines at the Wellcome Trust global heath charity said the Merck shot had already saved "countless lives" in the country. "Having this vaccine available under research conditions has been key in preventing the ongoing outbreak in the DRC spiraling into a repeat of the 2014-16 epidemic, where 11,000 people died," she told Reuters. Health authorities in Kinshasa said last week they planned to introduce an experimental second Ebola vaccine, developed by drugmaker Johnson & Johnson, in the country's eastern provinces in November. The Ebola virus causes hemorrhagic fever and spreads from person to person through direct contact with body fluids. It kills around half of those it infects. There are currently no licensed treatments for the deadly infection, but scientists said in August they were a step closer to being able to cure it after two experimental drugs showed survival rates of as much as 90% in a clinical trial in Congo. Claim: This is a photograph of a letter from C. Dennis Packee of Reiman's Harley-Davidson in Kewanee, Ill., to Christopher and Jamie Walters. The letter explains that Reiman's will store the Walters' motorcycles at no charge. It is their way of saying thank you to military members on deployment.
answer:
The world's first Ebola vaccine was recommended for approval by European drugs regulators on Friday in a move hailed by the World Health Organization (WHO) as a "triumph for public health" that would save many lives.